Mitsui Chemicals, Inc (MITUY) Fair Value & Analysis
Basic Materials · US · Market cap $4.1B
Analysis
Mitsui Chemicals, Inc (MITUY) currently trades at $11.21, while our model-based Fair Value estimate is $15.67 — implying the stock looks roughly 39.8% undervalued today. We read business quality at 88/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Mitsui Chemicals, Inc. engages in the mobility, life and health care, basic and green materials, ICT, and other businesses worldwide. The company offers vision care materials, nonwoven fabrics and personal care materials, agricultural chemicals, and oral care materials; and elastomers, performance and polypropylene compounds, and other materials. It also provides semiconductor solutions, such as electronic component processing materials, optical materials, and lithium-ion battery materials; functional food packaging materials; imaging solutions, such as lens materials, materials for reflective films, and LCD and OLED sealing materials; battery material solutions; and converting solutions, including heat sealants, barrier coating materials, and packaging adhesives. In addition, the company offers petrochemicals, which comprise ethylene, propylene, high- and low-density polyethylene; basic chemicals, such as phenol, bisphenol, acetone, isopropyl alcohol, methyl isobutyl ketone, purifi…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.